Clinical Trial Update: A Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.

View source ↗

Summary

This completed clinical trial from the Swiss Multiple Sclerosis Cohort evaluated whether disease-modifying therapies affect COVID-19 outcomes and the antibody r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Multiple Sclerosis, COVID-19 (Severe Coronavirus Disease 2019) | Status: COMPLETED